The NK1 receptor antagonist L822429 reduces heroin reinforcement

Neuropsychopharmacology

Volumn 38, Issue 6, 2013, Pages 976-984

  Barbier, Estelle ^a   Vendruscolo, Leandro F ^b   Schlosburg, Joel E ^b   Edwards, Scott ^b   Juergens, Nathan ^a   Park, Paula E ^b   Misra, Kaushik K ^b   Cheng, Kejun ^a   Rice, Kenner C ^a   Schank, Jesse ^a   Schulteis, Gery ^c   Koob, George F ^b   Heilig, Markus ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

heroin; neurokinin receptor; opioids; self administration; substance P

Indexed keywords

DIAMORPHINE; L 822429; NEUROKININ 1 RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EXPOSURE; DRUG SELF ADMINISTRATION; GENE; GENE EXPRESSION; LOCOMOTION; MALE; MAZE TEST; NONHUMAN; NUCLEUS ACCUMBENS; OBSERVATIONAL STUDY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TACR1 GENE;

ANIMALS; BEHAVIOR, ADDICTIVE; HEROIN; MALE; MOTIVATION; PIPERIDINES; RATS; RATS, WISTAR; RECEPTORS, NEUROKININ-1; REINFORCEMENT (PSYCHOLOGY); SELF ADMINISTRATION;

EID: 84878613499     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2012.261     Document Type: Article

References (33)

1. Ahmed SH, Koob GF (2005). Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology 180: 473-490.
2. Ahmed SH, Walker JR, Koob GF (2000). Persistent increase in the motivation to take heroin in rats with a history of drug escalation. Neuropsychopharmacology 22: 413-421.
3. Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P (2005). An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28: 321-329.
4. Barbano MF, Cador M (2006). Differential regulation of the consummatory, motivational and anticipatory aspects of feeding behavior by dopaminergic and opioidergic drugs. Neuropsychopharmacology 31: 1371-1381.
5. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL (1994). Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63.
6. Commons KG (2010). Neuronal pathways linking substance P to drug addiction and stress. Brain Res 1314: 175-182.
7. Dixon WJ (1980). Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 20: 441-462.
8. Ebner K, Muigg P, Singewald G, Singewald N (2008). Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci 1144: 61-73.
9. Ebner K, Rupniak NM, Saria A, Singewald N (2004). Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 101: 4280-4285.
10. Ebner K, Singewald N (2006). The role of substance P in stress and anxiety responses. Amino Acids 31: 251-272.
11. Edwards S, Koob GF (2010). Neurobiology of dysregulated motivational systems in drug addiction. Fut Neurol 5: 393-401.
12. Edwards S, Vendruscolo LF, Schlosburg JE, Misra KK, Wee S, Park PE et al (2012). Development of mechanical hypersensitivity in rats during heroin and ethanol dependence: alleviation by CRF receptor antagonism. Neuropharmacology 62: 1142-1151.
13. Furmark T, Appel L, Michelgard A, Wahlstedt K, Ahs F, Zancan S et al (2005). Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58: 132-142.
14. Gadd CA, Murtra P, De Felipe C, Hunt SP (2003). Neurokinin-1 receptor-expressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23: 8271-8280.
15. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C et al (2008). Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319: 1536-1539.
16. Jacobs EH, de Vries TJ, Smit AB, Schoffelmeer AN (2004). Gene transcripts selectively down-regulated in the shell of the nucleus accumbens long after heroin self-administration are up-regulated in the core independent of response contingency. FASEB J 18: 200-202.
17. Jacobs EH, Smit AB, de Vries TJ, Schoffelmeer AN (2005). Longterm gene expression in the nucleus accumbens following heroin administration is subregion-specific and depends on the nature of drug administration. Addict Biol 10: 91-100.
18. Kenny PJ, Chen SA, Kitamura O, Markou A, Koob GF (2006). Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci 26: 5894-5900.
19. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
20. Kramer MS, Winokur A, Kelsey J, Preskorn SH, Rothschild AJ, Snavely D et al (2004). Demonstration of the efficacy and safety of a novel substance P (NK1) receptor antagonist in major depression. Neuropsychopharmacology 29: 385-392.
21. Kuntz KL, Patel KM, Grigson PS, Freeman WM, Vrana KE (2008). Heroin self-administration: II. CNS gene expression following withdrawal and cue-induced drug-seeking behavior. Pharmacol Biochem Behav 90: 349-356.
22. Leffler A, Ahlstedt I, Engberg S, Svensson A, Billger M, Oberg L et al (2009). Characterization of species-related differences in the pharmacology of tachykinin NK receptors 1, 2 and 3. Biochem Pharmacol 77: 1522-1530.
23. Murtra P, Sheasby AM, Hunt SP, De Felipe C (2000). Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405: 180-183.
24. Ripley TL, Gadd CA, De Felipe C, Hunt SP, Stephens DN (2002). Lack of self-administration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 43: 1258-1268.
25. Ririe DG, Eisenach JC (2006). Age-dependent responses to nerve injury-induced mechanical allodynia. Anesthesiology 104: 344-350.
26. Robinson JE, Fish EW, Krouse MC, Thorsell A, Heilig M, Malanga CJ (2012). Potentiation of brain stimulation reward by morphine: effects of neurokinin-1 receptor antagonism. Psychopharmacology (Berl) 220: 215-224.
27. Schank JR, Pickens CL, Rowe KE, Cheng K, Thorsell A, Rice KC et al (2011). Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl) 218: 111-119.
28. Shurman J, Koob GF, Gutstein HB (2010). Opioids, pain, the brain, and hyperkatifeia: a framework for the rational use of opioids for pain. Pain Med 11: 1092-1098.
29. Singewald N, Chicchi GG, Thurner CC, Tsao KL, Spetea M, Schmidhammer H et al (2008). Modulation of basal and stressinduced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem 106: 2476-2488.
30. Thorsell A, Schank JR, Singley E, Hunt SP, Heilig M (2010). Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. Psychopharmacology (Berl) 209: 103-111.
31. Vendruscolo LF, Barbier E, Schlosburg JE, Misra KK, Whitfield TW Jr., Logrip ML et al (2012). Corticosteroid-dependent plasticity mediates compulsive alcohol drinking in rats. J Neurosci 32: 7563-7571.
32. Vendruscolo LF, Schlosburg JE, Misra KK, Chen SA, Greenwell TN, Koob GF (2011). Escalation patterns of varying periods of heroin access. Pharmacol Biochem Behav 98: 570-574.
33. Vendruscolo LF, Takahashi RN, Bruske GR, Ramos A (2003). Evaluation of the anxiolytic-like effect of NKP608, a NK1-receptor antagonist, in two rat strains that differ in anxietyrelated behaviors. Psychopharmacology (Berl) 170: 287-293.